Aurinia Capex To Operating Cash Flow vs Book Value Per Share Analysis

AUPH Stock

USD 8.98 0.03 0.34%

Aurinia Pharmaceuticals financial indicator trend analysis is way more than just evaluating Aurinia Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aurinia Pharmaceuticals is a good investment. Please check the relationship between Aurinia Pharmaceuticals Capex To Operating Cash Flow and its Book Value Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.

Capex To Operating Cash Flow vs Book Value Per Share

Capex To Operating Cash Flow vs Book Value Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aurinia Pharmaceuticals Capex To Operating Cash Flow account and Book Value Per Share. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Aurinia Pharmaceuticals' Capex To Operating Cash Flow and Book Value Per Share is -0.01. Overlapping area represents the amount of variation of Capex To Operating Cash Flow that can explain the historical movement of Book Value Per Share in the same time period over historical financial statements of Aurinia Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Aurinia Pharmaceuticals' Capex To Operating Cash Flow and Book Value Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Operating Cash Flow of Aurinia Pharmaceuticals are associated (or correlated) with its Book Value Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Book Value Per Share has no effect on the direction of Capex To Operating Cash Flow i.e., Aurinia Pharmaceuticals' Capex To Operating Cash Flow and Book Value Per Share go up and down completely randomly.

Correlation Coefficient

-0.01

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Capex To Operating Cash Flow

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Most indicators from Aurinia Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aurinia Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.As of now, Aurinia Pharmaceuticals' Selling General Administrative is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Enterprise Value is estimated to increase to about 1.5 B, while Tax Provision is projected to decrease to under 670.6 K.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	225.2M	239.8M	253.1M	265.7M
Cost Of Revenue	1.1M	5.7M	14.1M	7.6M

Total Operating Expenses Cost Of Revenue

Aurinia Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Non Current Assets Total	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Current Deferred Revenue	Cash	Non Currrent Assets Other	Cash And Short Term Investments	Other Liab
Total Assets		0.62	0.91	0.89	0.99	0.65	-0.32	-0.96	0.49	0.73	0.82	0.97	0.76	0.9	0.92	0.23	0.85	0.65	0.99	0.61	-0.26	0.6	0.58	0.1	0.98	0.44
Short Long Term Debt Total	0.62		0.63	0.87	0.49	0.99	0.4	-0.68	0.28	0.98	0.85	0.6	0.95	0.84	0.47	0.27	0.94	0.99	0.51	0.99	-0.2	0.01	-0.08	-0.1	0.45	0.05
Other Current Liab	0.91	0.63		0.93	0.89	0.68	-0.03	-0.9	0.25	0.75	0.88	0.85	0.66	0.87	0.85	0.32	0.81	0.68	0.89	0.59	-0.36	0.59	0.27	0.23	0.86	0.2
Total Current Liabilities	0.89	0.87	0.93		0.82	0.89	0.13	-0.92	0.34	0.93	0.96	0.85	0.88	0.96	0.79	0.33	0.97	0.89	0.83	0.84	-0.33	0.37	0.18	0.09	0.78	0.19
Total Stockholder Equity	0.99	0.49	0.89	0.82		0.52	-0.44	-0.93	0.48	0.62	0.74	0.95	0.65	0.82	0.92	0.2	0.75	0.52	1.0	0.48	-0.24	0.68	0.66	0.13	1.0	0.47
Property Plant And Equipment Net	0.65	0.99	0.68	0.89	0.52		0.4	-0.7	0.24	0.98	0.88	0.6	0.94	0.85	0.49	0.32	0.94	1.0	0.54	0.98	-0.3	0.07	-0.08	-0.11	0.48	0.01
Net Debt	-0.32	0.4	-0.03	0.13	-0.44	0.4		0.18	-0.41	0.3	0.24	-0.35	0.12	0.03	-0.33	0.22	0.13	0.4	-0.43	0.36	-0.12	-0.51	-0.95	0.04	-0.5	-0.59
Retained Earnings	-0.96	-0.68	-0.9	-0.92	-0.93	-0.7	0.18		-0.54	-0.76	-0.87	-0.96	-0.8	-0.93	-0.94	-0.3	-0.88	-0.69	-0.94	-0.66	0.21	-0.45	-0.44	-0.19	-0.91	-0.46
Accounts Payable	0.49	0.28	0.25	0.34	0.48	0.24	-0.41	-0.54		0.27	0.3	0.65	0.48	0.51	0.57	-0.11	0.43	0.24	0.5	0.25	0.07	0.16	0.53	0.03	0.51	0.9
Non Current Assets Total	0.73	0.98	0.75	0.93	0.62	0.98	0.3	-0.76	0.27		0.88	0.69	0.93	0.88	0.55	0.28	0.96	0.98	0.63	0.96	-0.19	0.18	0.02	-0.06	0.57	0.1
Net Receivables	0.82	0.85	0.88	0.96	0.74	0.88	0.24	-0.87	0.3	0.88		0.77	0.84	0.92	0.76	0.37	0.93	0.88	0.76	0.83	-0.36	0.33	0.05	0.16	0.7	0.1
Common Stock Shares Outstanding	0.97	0.6	0.85	0.85	0.95	0.6	-0.35	-0.96	0.65	0.69	0.77		0.75	0.88	0.93	0.16	0.82	0.6	0.96	0.58	-0.16	0.49	0.59	0.15	0.95	0.59
Non Current Liabilities Total	0.76	0.95	0.66	0.88	0.65	0.94	0.12	-0.8	0.48	0.93	0.84	0.75		0.91	0.64	0.26	0.97	0.94	0.68	0.95	-0.23	0.11	0.2	-0.11	0.63	0.27
Inventory	0.9	0.84	0.87	0.96	0.82	0.85	0.03	-0.93	0.51	0.88	0.92	0.88	0.91		0.86	0.31	0.96	0.85	0.85	0.81	-0.34	0.31	0.27	0.02	0.8	0.32
Other Current Assets	0.92	0.47	0.85	0.79	0.92	0.49	-0.33	-0.94	0.57	0.55	0.76	0.93	0.64	0.86		0.29	0.73	0.49	0.94	0.45	-0.3	0.5	0.54	0.23	0.92	0.5
Other Stockholder Equity	0.23	0.27	0.32	0.33	0.2	0.32	0.22	-0.3	-0.11	0.28	0.37	0.16	0.26	0.31	0.29		0.3	0.32	0.21	0.25	-0.47	0.1	-0.13	0.0	0.18	-0.04
Total Liab	0.85	0.94	0.81	0.97	0.75	0.94	0.13	-0.88	0.43	0.96	0.93	0.82	0.97	0.96	0.73	0.3		0.94	0.77	0.93	-0.28	0.24	0.2	-0.01	0.72	0.24
Property Plant And Equipment Gross	0.65	0.99	0.68	0.89	0.52	1.0	0.4	-0.69	0.24	0.98	0.88	0.6	0.94	0.85	0.49	0.32	0.94		0.54	0.98	-0.3	0.06	-0.08	-0.11	0.48	0.01
Total Current Assets	0.99	0.51	0.89	0.83	1.0	0.54	-0.43	-0.94	0.5	0.63	0.76	0.96	0.68	0.85	0.94	0.21	0.77	0.54		0.5	-0.26	0.65	0.66	0.13	1.0	0.48
Short Term Debt	0.61	0.99	0.59	0.84	0.48	0.98	0.36	-0.66	0.25	0.96	0.83	0.58	0.95	0.81	0.45	0.25	0.93	0.98	0.5		-0.18	-0.03	-0.05	-0.12	0.44	0.02
Intangible Assets	-0.26	-0.2	-0.36	-0.33	-0.24	-0.3	-0.12	0.21	0.07	-0.19	-0.36	-0.16	-0.23	-0.34	-0.3	-0.47	-0.28	-0.3	-0.26	-0.18		-0.16	0.02	0.17	-0.24	0.2
Current Deferred Revenue	0.6	0.01	0.59	0.37	0.68	0.07	-0.51	-0.45	0.16	0.18	0.33	0.49	0.11	0.31	0.5	0.1	0.24	0.06	0.65	-0.03	-0.16		0.58	0.19	0.67	0.32
Cash	0.58	-0.08	0.27	0.18	0.66	-0.08	-0.95	-0.44	0.53	0.02	0.05	0.59	0.2	0.27	0.54	-0.13	0.2	-0.08	0.66	-0.05	0.02	0.58		-0.08	0.71	0.64
Non Currrent Assets Other	0.1	-0.1	0.23	0.09	0.13	-0.11	0.04	-0.19	0.03	-0.06	0.16	0.15	-0.11	0.02	0.23	0.0	-0.01	-0.11	0.13	-0.12	0.17	0.19	-0.08		0.12	0.16
Cash And Short Term Investments	0.98	0.45	0.86	0.78	1.0	0.48	-0.5	-0.91	0.51	0.57	0.7	0.95	0.63	0.8	0.92	0.18	0.72	0.48	1.0	0.44	-0.24	0.67	0.71	0.12		0.51
Other Liab	0.44	0.05	0.2	0.19	0.47	0.01	-0.59	-0.46	0.9	0.1	0.1	0.59	0.27	0.32	0.5	-0.04	0.24	0.01	0.48	0.02	0.2	0.32	0.64	0.16	0.51

Click cells to compare fundamentals

Aurinia Pharmaceuticals Account Relationship Matchups

Aurinia Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	326.7M	463.7M	543.4M	470.9M	548.1M	575.5M
Other Current Liab	118K	27.8M	33.8M	37.4M	36.2M	38.0M
Total Current Liabilities	11.3M	32.0M	40.6M	46.1M	77.2M	81.0M
Total Stockholder Equity	273.5M	407.8M	479.1M	405.4M	378.0M	396.9M
Property Plant And Equipment Net	93K	10.3M	9.8M	8.6M	116.6M	122.4M
Net Debt	(306.0M)	(263.9M)	(223.2M)	(86.1M)	48.7M	51.2M
Retained Earnings	(539.8M)	(575.2M)	(756.1M)	(864.3M)	(942.3M)	(895.2M)
Accounts Payable	4.2M	2.6M	3.9M	3.1M	4.3M	3.3M
Non Current Assets Total	11.5M	44.2M	30.0M	28.3M	123.3M	129.4M
Net Receivables	368K	1.0M	15.4M	13.5M	24.1M	25.3M
Common Stock Shares Outstanding	93.0M	118.5M	129.4M	141.9M	143.2M	150.4M
Liabilities And Stockholders Equity	326.7M	463.7M	543.4M	470.9M	548.1M	575.5M
Non Current Liabilities Total	41.9M	23.9M	23.6M	19.3M	92.9M	97.6M
Other Current Assets	8.8M	7.2M	12.5M	14.9M	10.5M	11.0M
Other Stockholder Equity	23.7M	39.4M	59.0M	85.5M	120.8M	66.4M
Total Liab	53.2M	55.9M	64.3M	65.4M	170.1M	178.6M
Property Plant And Equipment Gross	93K	10.3M	9.8M	8.6M	118.5M	124.4M
Total Current Assets	315.1M	419.4M	513.3M	442.5M	424.8M	446.0M
Short Term Debt	6.9M	1.6M	2.1M	1.9M	31.2M	32.8M
Intangible Assets	11.2M	9.3M	8.4M	6.4M	5.0M	7.0M
Cash	306.0M	272.4M	231.9M	94.2M	48.9M	66.4M
Non Currrent Assets Other	209K	247K	11.8M	13.3M	1.5M	2.9M
Cash And Short Term Investments	306.0M	398.3M	466.1M	389.4M	350.5M	368.0M
Other Liab	14.4M	16.3M	16.0M	12.2M	14.0M	7.3M
Net Tangible Assets	289.7M	398.4M	470.7M	399.0M	458.9M	481.8M
Other Assets	209K	5.7M	11.8M	13.3M	15.3M	16.1M
Common Stock Total Equity	504.7M	790.5M	944.3M	1.2B	1.4B	1.4B
Common Stock	790.5M	944.3M	1.2B	1.2B	1.2B	1.3B
Property Plant Equipment	93K	4.8M	9.8M	8.6M	7.7M	8.1M
Capital Surpluse	24.7M	23.7M	39.4M	59.0M	67.9M	71.3M
Non Current Liabilities Other	12.3M	1.6M	16.0M	12.2M	10.9M	8.8M
Net Invested Capital	273.5M	407.8M	479.1M	405.4M	378.0M	349.2M

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:

How To Invest In Aurinia

Details

Is Aurinia Stock a good investment?

Details

What is Aurinia Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.15)

Revenue Per Share

1.536

Quarterly Revenue Growth

0.243

Return On Assets

(0.02)

Return On Equity

(0.06)

The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aurinia Capex To Operating Cash Flow vs Book Value Per Share Analysis

Capex To Operating Cash Flow vs Book Value Per Share

Capex To Operating Cash Flow vs Book Value Per Share Correlation Analysis

Correlation Coefficient

Capex To Operating Cash Flow

Book Value Per Share

Aurinia Pharmaceuticals fundamental ratios Correlations

Aurinia Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aurinia Pharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Total Current Assets
Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets

Common Stock Shares Outstanding	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Total Assets
Cash	- 0.95	Net Debt
Total Current Assets	- 0.94	Retained Earnings
Other Current Assets	- 0.94	Retained Earnings
Inventory	- 0.93	Retained Earnings